Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TTMVBWH)

• DTT Name: Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B) DTT Info
• Gene Name: HCV NS5B

Molecule-Related Drug & Molecule List

1 Approved Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PSI-7977	DMLSUWZ	HCV 1-6 infection	1E51	Approved	[1]

29 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
BI 207127	DMMSGAT	Hepatitis C virus infection	1E51.1	Phase 2	[2]
BMS 791325	DMKH4PI	Hepatitis C virus infection	1E51.1	Phase 2	[3]
Filibuvir	DMNSYXB	Hepatitis C virus infection	1E51.1	Phase 2	[4]
INX-189	DMSTJ6Q	Hepatitis C virus infection	1E51.1	Phase 2	[5]
Setrobuvir	DMTNDM2	Hepatitis C virus infection	1E51.1	Phase 2	[6]
Tegobuvir	DM6YI5T	Hepatitis C virus infection	1E51.1	Phase 2	[7]
Valopicitabine dihydrochloride	DMFWZ2U	Virus infection	1A24-1D9Z	Phase 2	[8]
VX-135	DMZ3FE8	Hepatitis C virus infection	1E51.1	Phase 2	[9]
VX-222	DMO3U4W	Hepatitis C virus infection	1E51.1	Phase 2	[10]
VX-759	DMJUSM8	Hepatitis C virus infection	1E51.1	Phase 2	[10]
AT-777	DM7O89Q	Hepatitis C	1E51	Phase 1/2	[11]
A-837093	DMX0JLI	Hepatitis C virus infection	1E51.1	Phase 1	[12]
ABT-072	DMG4H9Y	Hepatitis C virus infection	1E51.1	Phase 1	[13]
ABT-333	DM7TOWX	Hepatitis C virus infection	1E51.1	Phase 1	[13]
AT-787	DMHYO38	Hepatitis C	1E51	Phase 1	[11]
Balapiravir	DMAJPOX	Hepatitis C virus infection	1E51.1	Phase 1	[14]
CC-31244	DMAYHT4	Hepatitis C virus infection	1E51.1	Phase 1	[15]
Drug 2878175	DMNFEC6	Hepatitis virus infection	1E50-1E51	Phase 1	[16]
GS-6620	DMRDNPC	Hepatitis C virus infection	1E51.1	Phase 1	[17]
GSK-625433	DM7CIN4	Hepatitis C virus infection	1E51.1	Phase 1	[18]
IDX-189	DMYG3PZ	Hepatitis C virus infection	1E51.1	Phase 1	[19]
MBX-700	DMTXIZ1	Hepatitis C virus infection	1E51.1	Phase 1	[20]
MK-3281	DMG0Q27	Hepatitis C virus infection	1E51.1	Phase 1	[21]
PPI-383	DMEOJUN	Hepatitis C virus infection	1E51.1	Phase 1	[22]
PSI-938	DM5ZR4Q	Hepatitis C virus infection	1E51.1	Phase 1	[23]
RG-7348	DMFDKS7	Hepatitis C virus infection	1E51.1	Phase 1	[24]
TMC-647055	DMYEALO	Hepatitis C virus infection	1E51.1	Phase 1	[25]
TMC649128	DMAOV7M	Hepatitis C virus infection	1E51.1	Phase 1	[26]
VX-916	DMAJ2T4	Hepatitis C virus infection	1E51.1	Phase 1	[10]

13 Discontinued Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
HCV-796	DMPQSE4	Hepatitis C virus infection	1E51.1	Discontinued in Phase 2	[12]
IDX375	DMRPBJW	Hepatitis C virus infection	1E51.1	Discontinued in Phase 2	[27]
R7128	DM9BI3Y	Hepatitis C virus infection	1E51.1	Discontinued in Phase 2	[28]
R-803	DMRQPOD	Hepatitis C virus infection	1E51.1	Discontinued in Phase 1/2	[24]
AG-021541	DM1TYM4	Hepatitis C virus infection	1E51.1	Discontinued in Phase 1	[12]
HCV-086	DM2RF06	Hepatitis virus infection	1E50-1E51	Discontinued in Phase 1	[29]
JTK-109	DMUNYR7	Hepatitis C virus infection	1E51.1	Discontinued in Phase 1	[30]
JTK-652	DMZFEY1	Hepatitis C virus infection	1E51.1	Discontinued in Phase 1	[31]
JTK-853	DM64FX9	Hepatitis C virus infection	1E51.1	Discontinued in Phase 1	[32]
RG-7432	DMSUV3B	Hepatitis C virus infection	1E51.1	Discontinued in Phase 1	[33]
GSK-2485852	DMOALVR	Hepatitis C virus infection	1E51.1	Terminated	[34]
PSI-6130	DMWUOA8	Hepatitis C virus infection	1E51.1	Terminated	[35]
PSI-661	DM579WS	Hepatitis C virus infection	1E51.1	Terminated	[36]

2 Investigative Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
A-058	DMHSPRE	Hepatitis C virus infection	1E51.1	Investigative	[37]
PSI 7851	DM5ZU1V	Hepatitis C virus infection	1E51.1	Investigative	[38]

References

• [1] Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
• [2] 2011 Pipeline of Boehringer Ingelheim Pharma.
• [3] 2011 Pipeline of Bristol-Myers Squibb.
• [4] Clinical pipeline report, company report or official report of Pfizer (2011).
• [5] Clinical pipeline report, company report or official report of Bristol-Myers Squibb.
• [6] Clinical pipeline report, company report or official report of Anadys Pharmaceuticals (2011).
• [7] Clinical pipeline report, company report or official report of Gilead (2011).
• [8] Valopicitabine dihydrochloride:a specific polymerase inhibitor of hepatitis C virus. Curr Opin Investig Drugs. 2007 Feb;8(2):150-8.
• [9] All-oral HCV therapies near approval. Nat Rev Drug Discov. 2013 Jun;12(6):409-11.
• [10] 2011 Pipeline of Vertex.
• [11] Clinical pipeline report, company report or official report of Atea Pharmaceuticals.
• [12] Emerging drugs for hepatitis C. Expert Opin Emerg Drugs. 2008 Mar;13(1):1-19.
• [13] Clinical pipeline report, company report or official report of Abbott Laboratories (2011)
• [14] R-1626, a specific oral NS5B polymerase inhibitor of hepatitis C virus. IDrugs. 2008 Oct;11(10):738-49.
• [15] Clinical pipeline report, company report or official report of Cocrystal Pharma.
• [16] P1224 GSK2878175, A POTENT NON-NUCLEOSIDE INHIBITOR OF HCV NS5B WITH PAN-GENOTYPIC ACTIVITY. Journal of Hepatology Volume 60, Issue 1, Supplement, April 2014, Pages S496.
• [17] Inhibition of hepatitis C virus replication by GS-6620, a potent C-nucleoside monophosphate prodrug. Antimicrob Agents Chemother. 2014;58(4):1930-42.
• [18] Preclinical Characterization of PF-00868554, a Potent Nonnucleoside Inhibitor of the Hepatitis C Virus RNA-Dependent RNA Polymerase . Antimicrob Agents Chemother. 2009 June; 53(6): 2544-2552.
• [19] Clinical pipeline report, company report or official report of Idenix (2011).
• [20] Clinical pipeline report, company report or official report of Microbiotix Inc.
• [21] Clinical pipeline report, company report or official report of Merck (2011).
• [22] 1173 IDENTIFICATION AND CHARACTERIZATION OF PPI-383, A NEXT GENERATION HCV NS5B NON-NUCLEOSIDE INHIBITOR WITH POTENT ACTIVITY AGAINST ALL MAJOR HCV GENOTYPES. Journal of Hepatology Volume 56, Supplement 2, April 2012, Pages S464.
• [23] 2011 Pipeline of Pharmasset.
• [24] Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
• [25] WO patent application no. 2014,1522,75, Deuterium modified derivatives of the ns5b polymerase inhibitor tmc647055.
• [26] Clinical pipeline report, company report or official report of Medivir (2011).
• [27] Therapy with amineptine, a dopamine reuptake inhibitor, in patients with major depression. Indian J Psychiatry. 1997 Apr;39(2):147-53.
• [28] Clinical pipeline report, company report or official report of Roche (2009).
• [29] Challenges and successes in developing new therapies for hepatitis C. Nature. 2005 Aug 18;436(7053):953-60.
• [30] Benzimidazole derivatives bearing substituted biphenyls as hepatitis C virus NS5B RNA-dependent RNA polymerase inhibitors: structure-activity relationship studies and identification of a potent and highly selective inhibitor JTK-109. J Med Chem. 2006 Jul 27;49(15):4721-36.
• [31] Safety and antiviral activity of JTK-652: a novel HCV infection inhibitor. Antivir Ther. 2010;15(5):765-73.
• [32] Preclinical Characterization of JTK-853, a Novel Nonnucleoside Inhibitor of the Hepatitis C Virus RNA-Dependent RNA Polymerase. Antimicrob Agents Chemother. 2012 August; 56(8): 4250-4256.
• [33] Chutes and Ladders in Hepatitis C Nucleoside Drug Development. Antiviral Res. 2014 February; 102: 119-147.
• [34] In vitro characterization of GSK2485852, a novel hepatitis C virus polymerase inhibitor. Antimicrob Agents Chemother. 2013 Nov;57(11):5216-24.
• [35] An efficient and diastereoselective synthesis of PSI-6130: a clinically efficacious inhibitor of HCV NS5B polymerase. J Org Chem. 2009 Sep 4;74(17):6819-24.
• [36] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [37] The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
• [38] Mechanism of activation of PSI-7851 and its diastereoisomer PSI-7977.J Biol Chem.2010 Nov 5;285(45):34337-47.